Danaher Corporation $DHR Shares Sold by Arlington Partners LLC

Key Points

• Arlington Partners LLC reduced its stake in Danaher Corporation by 28.9% during the 2nd quarter, selling 5,561 shares and retaining a total of 13,653 shares valued at approximately $2.7 million.
• In recent insider activity, Director Teri List sold 2,778 shares at an average price of $211.06, marking an 11.81% decrease in her ownership.
• Danaher Corporation reported a quarterly earnings of $1.80 per share, exceeding analysts' estimates, and set a guidance for FY 2025 at $7.700 to $7.800 EPS.

Arlington Partners LLC lowered its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 28.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 13,653 shares of the conglomerate's stock after selling 5,561 shares during the quarter. Arlington Partners LLC's holdings in Danaher were worth $2,697,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. MGO One Seven LLC increased its holdings in Danaher by 485.7% during the 1st quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate's stock worth $5,145,000 after purchasing an additional 20,813 shares in the last quarter. UniSuper Management Pty Ltd lifted its stake in Danaher by 1.6% during the first quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate's stock worth $34,954,000 after purchasing an additional 2,667 shares during the last quarter. Asahi Life Asset Management CO. LTD. bought a new stake in shares of Danaher during the 1st quarter valued at approximately $539,000. Horizon Financial Services LLC boosted its stake in shares of Danaher by 20,400.0% during the first quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate's stock valued at $1,681,000 after purchasing an additional 8,160 shares in the last quarter. Finally, Focus Partners Wealth raised its position in Danaher by 10.7% during the 1st quarter. Focus Partners Wealth now owns 196,682 shares of the conglomerate's stock worth $40,328,000 after purchasing an additional 19,086 shares during the last quarter. Institutional investors own 79.05% of the company's stock.

Danaher Trading Down 1.5%

NYSE DHR traded down $2.99 on Monday, hitting $190.30. 2,949,617 shares of the stock were exchanged, compared to its average volume of 3,371,563. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The firm has a market capitalization of $136.26 billion, a P/E ratio of 40.49, a P/E/G ratio of 2.70 and a beta of 0.75. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.90. The stock has a fifty day moving average price of $200.02 and a two-hundred day moving average price of $198.03.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.16. The business had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm's quarterly revenue was up 3.4% compared to the same quarter last year. During the same quarter last year, the firm earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Research analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Friday, September 26th. Danaher's payout ratio is presently 27.23%.

Insider Transactions at Danaher

In other news, Director Teri List sold 2,778 shares of the business's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director owned 20,751 shares of the company's stock, valued at $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 11.20% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

DHR has been the topic of a number of research reports. Wall Street Zen raised Danaher from a "hold" rating to a "buy" rating in a research report on Friday, June 27th. Robert W. Baird raised their price target on shares of Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a report on Friday, July 18th. Deutsche Bank Aktiengesellschaft reduced their target price on Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Wells Fargo & Company cut their price target on Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 23rd. Finally, Barclays reaffirmed an "overweight" rating and issued a $225.00 price objective (up from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Seventeen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $245.91.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.